The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.

The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.

The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.

The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.

Multiple Sclerosis

1-gram marijuana cigarette smoked once per day for 3 months

Medical Marijuana

Matching 1 gram placebo cigarette smoked once per day for 3 months

Placebo

The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis

Thorsten Rudroff

Assistant Professor

Colorado State University

Patients who receive Dronabinol 5 mg, every other night, orally.

Patients who receive Placebo every other night, orally

Esophageal Diseases

Dronabinol 5 mg, every other night, orally

Dronabinol

Temple University Hospital

Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain

Patient will fill out a Chest Pain Questionnaire and symptom diary daily of symptoms which will be normalized to a numerical value for comparison among groups.

Patients will fill out a questionnaire pertaining to GERD symptoms which will be normalized to a numerical value for comparison among groups.

A general health-related quality of life questionnaire that examines 8 domains: Physical Functioning, Role Functioning Physical, Role Functioning Emotional, Mental Health, Vitality, Bodily Pain, General Health, and Social Functioning

Sensory thresholds for first sensation, discomfort, and pain in the esophagus. Frequency, amplitude, area under the curve (AUC) of reactive esophageal contractions

Analysis of depressive symptoms normalized to a numerical value for comparison among groups.

Total cholesterol will be measured and reported in mg/dL.

Analysis of anxious symptoms normalized to a numerical value for comparison among groups.

Non-HDL cholesterol will be measured and reported in mg/dL.

HDL cholesterol will be measured and reported in mg/dL.

Triglycerides will be measured and reported in mg/dL.

Glucose will be measured and reported in mg/dL.

Insulin will be measured and reported in µU/mL.

Leptin will be measured and reported in ng/mL.

Leptin will be measured and reported in IU/L.

LDH will be measured and reported in IU/L.

CRP will be measured and reported in mg/L.

Temple University

Marinol

Total

Sex: Female, Male

Region of Enrollment

Number of people still experiencing the same amount of chest pain during treatment than previously without

Frequency of Chest Pain Episodes

Total (intensity (0(none) - 3(severe) + duration (0(none) - 3(longer than 30 mins)) at end of 1 month treatment; higher represents worse outcome; the total score ranges from 0 to 6 and is the sum of the intensity and duration

Frequency of Chest Pain in Treatment Group vs Baseline

Intensity (0(none) - 3(severe)) at baseline vs 1 month for chest pain episodes; higher represents worse outcome; multiple chest pain totals are averaged

Intensity of Chest Pain Episodes

This is determined by the Esophageal Balloon Distension Test; range 0-65 mmHg

Sensory Thresholds for First Sensation

0 - is none and 3 is longer than 30 mins; higher values is worst outcome; chest pain totals are averaged

Duration of Chest Pain Episodes

When participants felt pain at earliest pressure; range 0-65 mmHg

Sensory Thresholds for Discomfort

When highest amount of pain was felt; range is 0-65 mmHg

hypersensitivity/konopa

The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis

Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain

The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain

Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis

Najkompletnejšia databáza liečivých bylín podporovaná vedou